Office of Regulatory Management

Economic Review Form

Agency name	Board of Pharmacy, Department of Health Professions	
Virginia Administrative	18VAC110-20	
Code (VAC) Chapter citation(s)		
VAC Chapter title(s)	Regulations Governing the Practice of Pharmacy	
Action title	June 2023 scheduling of Chemicals in Schedule I	
Date this document prepared	July 14 th , 2023	
Regulatory Stage (including Issuance of Guidance Documents)	Exempt	

Cost Benefit Analysis

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

(1) Direct &	There are no direct or indirect	et costs of the change to the agency. There	
Indirect Costs &	are no direct or indirect benefits of the change. This change solely adds		
Benefits	chemicals to Schedule I base	<u> </u>	
(Monetized)		-	
	This change likely adds costs for law enforcement entities and prosecution entities in the Commonwealth, because the number of substances that it is illegal to possess or use increases. The cost for this change is unquantifiable by the Board, however, because the changes are speculative and involve agencies and entities in the Commonwealth with their own financial considerations of which the Board is not aware. Due to this limitation, no costs or benefits are provided below.		
(2) Present			
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits	
	(a) 0	(b) 0	
(3) Net Monetized Benefit	0	L	
(4) Other Costs & Benefits (Non- Monetized)	0		
(5) Information			

Table 1a: Costs and Benefits of the Proposed Changes (Primary Option)

Table 1b: Costs and Benefits under the Status Quo (No change to the regulation)

(1) Direct &Indirect Costs &Benefits(Monetized)	There are no direct or indirect costs to status quo. No direct or indirect benefits to status quo.			
(2) Present				
Monetized Values	Direct & Indirect Costs Direct & Indirect Benefits			
	(a)	(b)		
(3) Net Monetized Benefit				
(4) Other Costs & Benefits (Non- Monetized)				

_

(5) Information	
Sources	

Table 1c: Costs and Benefits under Alternative Approach(es)

Tuble Ict Costs and	Denemits under Alternative A			
(1) Direct &	There are no alternative approaches to scheduling actions under Virginia			
Indirect Costs &	Code § 54.1-3443(D).			
Benefits				
(Monetized)				
(2) Present				
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits		
	(a) (b)			
(3) Net Monetized				
Benefit				
(4) Other Costs &				
Benefits (Non-				
Monetized)				
(5) Information				
Sources				
Sources				

Impact on Local Partners

Use this chart to describe impacts on local partners. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 2: Impact on Local Partners

Tuble 21 Impact on			
(1) Direct & Indirect Costs &	Please see Table 1a for impacts on local partners. This impact is unquantifiable by the Board, however, so no costs or benefits are		
Benefits	included below.		
(Monetized)			
(2) Present			
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits	
	(a)	(b)	
(3) Other Costs &			
Benefits (Non-			
Monetized)			

(4) Assistance	
(5) Information Sources	

Impacts on Families

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 3: Impact on Families

Table 5. Impact on	r annines	
(1) Direct &	There is no impact on families.	
Indirect Costs &		
Benefits		
(Monetized)		
(2) Present		
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Other Costs &		
Benefits (Non-		
Monetized)		
(4) Information		
Sources		
Sources		

Impacts on Small Businesses

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 4: Impact on Small Businesses

(1) Direct &	There is no impact on small businesses.		
Indirect Costs &			
Benefits			
(Monetized)			
(2) Present			
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits	
	(a)	(b)	

(3) Other Costs & Benefits (Non- Monetized)	
(4) Alternatives	
(5) Information Sources	

Changes to Number of Regulatory Requirements

Table 5: Regulatory Reduction

For each individual action, please fill out the appropriate chart to reflect any change in regulatory requirements, costs, regulatory stringency, or the overall length of any guidance documents.

Change in Regulatory Requirements

VAC Section(s) Involved	Initial Count	Additions	Subtractions	Net Change
18VAC110-20- 322	1	0	0	0

Cost Reductions or Increases (if applicable)

VAC Section(s) Involved	Description of Regulatory Requirement	Initial Cost	New Cost	Overall Cost Savings/Increases

Other Decreases or Increases in Regulatory Stringency (if applicable)

VAC Section(s) Involved	Description of Regulatory	Overview of How It Reduces	
	Change	or Increases Regulatory	
		Burden	
18VAC110-20-322	Adds chemicals and drugs to	There is no increase or	
	Schedule I.	decrease in the regulatory	
		burden because practitioners	
		are not required to take any	
		action. Additionally, this	
		change is only effective for 18	
		months. If the General	
		Assembly acts to place these	
		scheduled drugs in Code, the	
		Board will delete these	
		additions following the	
		effective date of changes made	
		in the next General Assembly	
		Session. Rarely, the General	
		Assembly will not act to	
		permanently place drugs in	
		Schedule I that the Board has	
		placed there. If that occurs, the	
		Board will delete the changes	

	after the 18 month effective window has closed.

Length of Guidance Documents (only applicable if guidance document is being revised)

Title of Guidance Document	Original Length	New Length	Net Change in Length